Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2000
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Primary revenue drivers include EPOGEN (Epoetin alfa) and NEUPOGEN (Filgrastim).
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Sept 30, 2000 |
9 Months Ended Sept 30, 2000 |
3 Months Ended Sept 30, 1999 |
9 Months Ended Sept 30, 1999 |
|---|---|---|---|---|
| Total Revenues | $949.5 | $2,678.0 | $847.2 | $2,413.2 |
| Net Income | $358.9 | $927.7 | $300.0 | $814.8 |
| Diluted EPS | $0.33 | $0.86 | $0.28 | $0.76 |
| Operating Cash Flow | N/A | $1,262.9 | N/A | $994.4 |
| Cash & Equivalents | $159.8 | $159.8 | $130.9 | $130.9 |
| Marketable Securities | $1,706.9 | $1,706.9 | $1,202.1 | $1,202.1 |
| Total Debt (Long-term + CP) | $322.2 | $322.2 | $322.5 | $322.5 |
| Effective Tax Rate | 32.3% | 31.5% | 33.7% | 31.0% |
Note: Total Debt includes $223.0 million long-term debt and $99.2 million commercial paper.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 12% ($102.3 million) for the quarter and 11% ($264.8 million) for the nine months compared to the prior year periods. Product sales grew 11% and 7% respectively.
- Profitability: Net income rose 20% for the quarter and 14% for the nine months. This was significantly aided by a $73.9 million legal award recorded in Q3 2000 (compared to $49.0 million in Q3 1999) related to arbitration costs with Johnson & Johnson.
- Expense Increases: Selling, general, and administrative (SG&A) expenses increased 27% for the quarter and 28% for the nine months, driven by higher staff costs and marketing expenses. R&D expenses increased slightly (2% and 3% respectively).
- Cash Flow: Net cash provided by operating activities increased 27% to $1,262.9 million for the nine months ended Sept 30, 2000, compared to $994.4 million in the prior year.
- Product Performance: EPOGEN sales grew 11% (quarter) and 12% (nine months). NEUPOGEN sales grew 13% (quarter) but only 1% (nine months) due to foreign exchange headwinds and Y2000 inventory effects.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2000 Guidance Revision:
- EPOGEN: Full-year sales growth revised down to "low double digits" from "low teens" due to moderated demand growth.
- NEUPOGEN: Full-year sales expected to be slightly less than 1999 levels, down from previous guidance of "approximately the same," due to softened demand and a stronger U.S. dollar.
- EPS: Excluding the legal award and an expected $30 million charge for the Kinetix acquisition, 2000 EPS is expected to be at the low end of the previous $1.06–$1.08 guidance.
- 2001 Outlook:
- Combined EPOGEN and ARANESP sales expected to grow in the "high teens to low twenties" over 2000 EPOGEN sales.
- NEUPOGEN sales growth expected in the "high single digits."
- Total product sales growth expected in the "mid to high teens."
Risks and Contingencies
- Johnson & Johnson Arbitration: While Amgen won a $78 million award for costs/expenses, it has filed a demand to terminate J&J's license for selling PROCRIT into Amgen's exclusive dialysis market. The trial is set for September 2001; the outcome is unpredictable.
- Acquisition Charge: The pending acquisition of Kinetix Pharmaceuticals is expected to result in a non-recurring after-tax charge of approximately $30 million ($0.03 per share) to write off in-process R&D.
- Reimbursement and Competition: Sales are sensitive to federal reimbursement rates (Medicare/Medicaid) and competition, particularly for NEUPOGEN as chemotherapy regimens evolve.
- Legal Proceedings: Ongoing litigation with Biogen (regarding NEUPOGEN and INFERGEN) and Transkaryotic Therapies/Aventis. Recent judgments favored Amgen in Biogen and Genentech cases, though appeals or further proceedings may occur.
Investor Verification Checklist
- Legal Award Sustainability: Verify the finality of the $73.9 million legal award and the status of the counter-claim regarding J&J's license termination.
- Acquisition Impact: Confirm the closing of the Kinetix acquisition and the exact timing of the $30 million R&D write-off charge.
- Product Mix Shift: Monitor the transition from EPOGEN to ARANESP and the impact on 2001 combined sales growth targets.
- Foreign Exchange Sensitivity: Assess the impact of the strengthening U.S. dollar on international NEUPOGEN sales in 2001.
- Capital Allocation: Review the remaining $1.0 billion stock repurchase authorization and the company's ability to fund the $450–$500 million capital expenditure plan for 2000.